Dyne Therapeutics, Inc. (DYN) Stock

Dyne Therapeutics, Inc. (DYN) is a Healthcare stock trading at $19.80 (as of 2026-06-18), with a market capitalization of $3.19B and a trailing P/E of -6.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Dyne Therapeutics, Inc. is a biotechnology company developing therapeutics for genetically driven muscle diseases in the United States. Its pipeline includes programs for conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as other rare skeletal muscle, cardiac, and metabolic muscle diseases.

Valuation — source: SEC EDGAR (first-party)

Price	$19.80
Market Cap	$3.19B
P/E Ratio	-6.3
EV / EBITDA	-5.7
Price / Book	3.78
DCF Value (model)	$-37.28
DCF Upside vs Price	-288.3%

Profitability & Growth — source: SEC EDGAR

Return on Equity	-52.2%
Debt / Equity	0.17
Current Ratio	19.92

Valuation vs Sector & Industry

Stock P/E	-6.3
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-130.0%
vs Industry	-136.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures

Top Institutional Holder	T. Rowe Price Investment Management, Inc. ($558.15M)
Institutional Holders Tracked	10

Company

Sector	Healthcare
Industry	Pharmaceutical Products
CEO	John G. Cox
Employees	192
Country	US
IPO Date	2020-09-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• Arcutis Biotherapeutics, Inc. (ARQT)
• CG Oncology, Inc. Common stock (CGON)
• Kiniksa Pharmaceuticals, Ltd. (KNSA)
• IDEAYA Biosciences, Inc. (IDYA)
• Nuvation Bio Inc. (NUVB)
• Disc Medicine, Inc. (IRON)
• Arcus Biosciences, Inc. (RCUS)
• Mineralys Therapeutics, Inc. (MLYS)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.